REGENERON
SCIENCE TO MEDICINE®

Benign Hematology Areas of Interest

(Investigator Initiated Studies and Research Collaborations)

REGN3918 (C5) pozelimab
REGN3918 (C5) pozelimab + cemdisiran (ALN-CC5)

Interventional proposals in Myasthenia Gravis (MG):

- *Mechanistic*
  - *Biomarkers leading to better characterization, management, and treatment options*
  - *Complement levels during disease progression*
- *Special Populations*
  - *Triple-negative*
  - *Seronegative*
  - *Myasthenic crisis*
  - *Poor responders on non-C5 inhibiting therapies*
- *Patient Monitoring*
  - *Geocaching*
  - *Wearable devices to monitor disease or patient Quality of Life (QoL)*
- *Indirect Treatment Comparisons/Switching Data*
  - *Early intervention with pozelimab*
  - *Switching within the C5 inhibitor class*
  - *Switching off rituximab, IVIg, or PLEX*
- *Observational Studies*
  - *Epidemiology*
  - *Real World Evidence (RWE)*
  - *Registries*
  - *Database*

Interventional proposals in Paroxysmal Nocturnal Hemoglobinuria (PNH):

- *Mechanistic*
  - *Biomarkers leading to better patient stratification*
  - *Complement levels during disease progression*
  - *Drug interactions*
- *Special Populations*
  - *Poor responders on non-C5 inhibiting therapies*
  - *Patients that have recovered (natural resolution)*
  - *Breakthrough hemolysis*
- *Patient Monitoring*
  - *Geocaching*
  - *Wearable devices to monitor disease or patient QoL*
- *Indirect Treatment Comparisons/Switching Data*
  - *Switching within the C5 inhibitor class*
  - *Switching to a C5 inhibitor from non-C5 inhibiting therapies*
  - *Switching off rituximab, IVIg, or PLEX*
- *Observational Studies*
  - *Epidemiology*
  - *RWE*
  - *Registries*
  - *Database*
  - *Patient Reported Outcomes (PRO) in patients using the PNH Specific Questionnaire*

Note that Regeneron cannot currently accept any proposals for Investigator Sponsored Studies or Research Collaborations using REGN3918 (C5) pozelimab and REGN3918 (C5) pozelimab + cemdisiran (ALN-CC5) in the European Union